Canakinumab  (Synonyms: Ilaris; ACZ 885)

Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin^[1][2].

Human IgG1(K214R) kappa

Human IgG1 (K214R) kappa, Isotype Control

Human

IC50: 43.6 pM (human IL-1β), 40.8 pM (marmoset IL-1β)^[2]

Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC₅₀s of 43.6 and 40.8 pM for human and marmoset IL-1β^[2]. Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

914613-48-2

Liquid

Colorless to light yellow

[Canakinumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IL-1 beta Protein, Human (HY-P7028) can bind Canakinumab. The EC₅₀ for this effect is 6.151 ng/mL.

• [1]. Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15.  [Content Brief]

  [2]. Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151-60.  [Content Brief]